The dual BCL-XL/BCL-2 inhibitor Navitoclax was also shown to synergise with BETi in small cell lung cancer, colorectal cancer, glioma and B-cell lymphomas [299,300,301,302], whilst BH3-mimetics targeting MCL-1 enhance BETi activity in AML and melanoma [292,303]. Here, BCL2L1 is linked to colorectal cancer.